HUTCHMED Limited and AstraZeneca PLC have initiated SAMETA, a global Phase III study of savolitinib, an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in combination with AstraZeneca’s PD-L1 inhibitor IMFINZI® in patients with MET-driven advanced papillary renal cell carcinoma.
October 31, 2021
· 14 min read
